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Abstract 
Background: Severe infections and multidrug-resistant pathogens are common in critically ill patients. Antimicrobial 
stewardship (AMS) and therapeutic drug monitoring (TDM) are contemporary tools to optimize the use of antimi-
crobials. The A-TEAMICU survey was initiated to gain contemporary insights into dissemination and structure of AMS 
programs and TDM practices in intensive care units.
Methods: This study involved online survey of members of ESICM and six national professional intensive care 
societies.
Results: Data of 812 respondents from mostly European high- and middle-income countries were available for 
analysis. 63% had AMS rounds available in their ICU, where 78% performed rounds weekly or more often. While 82% 
had local guidelines for treatment of infections, only 70% had cumulative antimicrobial susceptibility reports and 
56% monitored the quantity of antimicrobials administered. A restriction of antimicrobials was reported by 62%. TDM 
of antimicrobial agents was used in 61% of ICUs, mostly glycopeptides (89%), aminoglycosides (77%), carbapenems 
(32%), penicillins (30%), azole antifungals (27%), cephalosporins (17%), and linezolid (16%). 76% of respondents used 
prolonged/continuous infusion of antimicrobials. The availability of an AMS had a significant association with the use 
of TDM.
Conclusions: Many respondents of the survey have AMS in their ICUs. TDM of antimicrobials and optimized admin-
istration of antibiotics are broadly used among respondents. The availability of antimicrobial susceptibility reports and 
a surveillance of antimicrobial use should be actively sought by intensivists where unavailable. Results of this survey 
may inform further research and educational activities.
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Background
Antimicrobial resistance (AMR) is a concern in many 
regions of the world [1]. Antimicrobial use and hori-
zontal spread of bacteria have been recognized as the 
most important drivers of resistance and its dissemina-
tion [2, 3]. In addition to infection prevention measures, 
antimicrobial stewardship (AMS) is an essential step to 
optimize consumption of antimicrobials and thus reduce 
bacterial resistance [4–6].
Intensive care units (ICUs) are burdened by large num-
bers of patients with infections and sepsis, high antimi-
crobial use, and high rates of resistance [7]. Therefore, 
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the rational management of anti-infectives and infection 
control measures are core competencies of intensive care 
medicine specialists [8]. In 2016, experts from the Euro-
pean Society of Intensive Care Medicine (ESICM) and 
the European Society of Clinical Microbiology and Infec-
tious Diseases (ESCMID) in collaboration with the World 
Alliance Against Antimicrobial Resistance (WAAAR) 
held a round table meeting on antimicrobial resistance 
[9]. Besides the improvement of awareness for AMR and 
surveillance, the engagement of intensivists in multidis-
ciplinary AMS teams in the hospital was recommended. 
Along the same lines, AMR and AMS were identified 
as integral components of the intensive care medicine 
research agenda to be addressed in the future [10].
In addition to a reduction of antimicrobial use to 
diminish ecological pressure in the ICU environment, 
pharmacologic optimization of antimicrobial administra-
tion is recognized as an important target in critically ill 
patients. Standard dosing regimens for many antimicro-
bials were shown to be associated with extremely variable 
drug levels [11], potentially causing unacceptable rates 
of underdosing and adverse outcomes [12, 13]. Further-
more, the international ADMIN-ICU survey found a 
marked heterogeneity of dosing strategies and the use of 
therapeutic drug monitoring (TDM) [14].
The “Antimicrobial Stewardship, Therapeutic Drug 
Monitoring and Early Appropriate infection Manage-
ment in European ICUs” (A-TEAMICU) survey was 
initiated by the Infection Section of the ESICM to gain 
insights into the development of AMS programs and 
TDM practices in ICUs since the publication of ADMIN-
ICU in 2015 and the 2016 round table meeting on anti-
microbial resistance. Results from this survey can be the 
basis for educational initiatives on behalf of ESICM by 
providing real-world information on the dissemination 
and structure of AMS and TDM. We hypothesized that 
AMS programs, the availability of TDM and the use of 
pharmacologically optimized infusion of antimicrobials 
have markedly increased in comparison to prior surveys.
Methods
Survey population
The survey was endorsed by ESICM and six national 
professional societies (Australia and New Zealand, Ger-
many, Brazil, United Kingdom, the Netherlands, and 
Portugal). The societies used their respective members 
email addresses to send a link to an online survey. Due 
to data protection regulations, the numbers of profes-
sionals who were contacted and their email addresses 
remained unknown to the A-TEAMICU investigators. 
The survey was conducted in English, participation was 
voluntary (i.e., there was no financial remuneration), 
and respondents remained anonymous. The number 
of participants from a single center or hospital was not 
controlled.
Data collection
The A-TEAMICU study group consists of experts with 
clinical expertise in intensive care medicine, infectious 
diseases, and antimicrobial stewardship who are mem-
bers of the “Infection Section” of ESICM. The idea to 
conduct this survey was formulated during a section 
meeting. Participation in this project was open to eve-
ryone interested in the topic. Using a recent survey on 
AMS by the “ESCMID Study Group in Antimicrobial 
Stewardship (ESGAP)” as a starting point [15], questions 
were modified to the ICU setting by the authors of this 
publication. The questions were preformulated and dis-
cussed by the group in video/telephone conferences. All 
questions were consented by the whole group. The final 
core survey consisted of 23 questions. Dependent on 
the participants’ answers, 13 additional questions were 
asked (Additional file 1). The questionnaire was divided 
into four sections (hospital information, organization of 
an antimicrobial stewardship program, therapeutic drug 
monitoring, education in antimicrobial stewardship). The 
A-TEAMICU survey used the “Survey Monkey” platform 
which was provided by ESICM.
Before starting the survey, ethical approval was sought 
at the University of Ulm (Germany). The local ethics 
committee waived the need for formal ethical approval of 
A-TEAMICU as an anonymous online survey of clinical 
practice.
Descriptive statistics were expressed as total numbers 
and percentages for categorical variables. Sample size 
calculations were not performed, as it is not possible 
to estimate the number of participants before the sur-
vey. Due to this, we only performed univariate analyses 
for categorical variables, using the Chi-squared test. A 
p-value < 0.05 was considered statistically significant.
Results
Demographic information
In total, 812 participants from 71 countries responded to 
the survey (Fig. 1). The countries of origin were classified 
using the criteria of the Statistics Division of the United 
Nations [16] (Table 1). The majority (85%) of respondents 
worked in high-income countries, while 14% participated 
from upper-middle and lower–middle-income countries. 
Seven respondents did not provide information about 
their country of origin.
To our knowledge, this is the largest survey on this 
topic.
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Part 1: hospital information and demographics
Respondents were generally experienced ICU clinicians 
and a substantial proportion considered themselves unit 
leaders in infection management. 8% of participants 
have experience in the ICU of less than 2 years, 15% have 
2–5  years, 19% 5–10  years, 33% 10–20  years, and 25% 
reported experience of more than 20  years. Approxi-
mately half reported having received specific training in 
antimicrobial therapy or infection management. 35% of 
respondents considered themselves the most qualified 
intensivist on their respective service regarding infec-
tion management. Detailed information about the hospi-
tal types and the numbers of ICU beds are included in 
Table 1.
Infectious disease (ID) specialists were available for 
consultations in 67% of hospitals, with a further 16% 
available as external consultants. Clinical microbiolo-
gists were available for in-house consultation in 60% of 
hospitals, while 22% had availability of external consulta-
tion. A lack of ID support was reported by 16% of partici-
pants; 17% cannot consult a clinical microbiologist. Most 
respondents use an electronic medical record in the ICU 
(59%).
Part 2: AMS and infection management
A formal antimicrobial stewardship program (ASP) 
existed in 69% of hospitals, and 63% of participants had 
an ASP available in their ICU. Common members of the 
A-team were clinical microbiologists (62%), infectious 
disease specialists (57%), clinical pharmacists (50%), and 
Fig. 1 Countries from which participants took part in the A-TEAMICU survey
Table 1 Demographic information
Characteristic Numbers (%)
Region of origin
 Europe and Central Asia 641 (80%)
 Latin America and Caribbean 61 (8%)
 East Asia and Pacific Region 38 (5%)
 Middle East and North Africa 27 (3%)
 South Asia 24 (3%)
 North America 8 (1%)
 Sub-Saharan Africa 6 (0.7%)
Type of hospital
 Academic hospital 416 (52%)
 Non-academic teaching hospital 275 (34%)
 General non-teaching hospital 114 (14%)
Numbers of ICU beds
 ≤ 10 156 (19%)
 11–20 226 (28%)
 21–30 123 (15%)
 31–40 89 (11%)
 41–50 44 (5%)
 > 50 163 (20%)
Page 4 of 8Lanckohr et al. Ann. Intensive Care          (2021) 11:131 
infection prevention specialists (21%). In 77% of ICUs 
with availability of an ASP team, the intensivist was 
member of the team. The A-team visited the ICU weekly 
in 37% of hospitals; 41% had rounds of the A-team more 
often (several times a week in 21%, daily in 20% of ICUs). 
14% of respondents had the A-team only available on 
demand.
A restriction of selected antimicrobials with the neces-
sity for formal authorization was in place in 62% of hos-
pitals. Detailed information on the methods used for the 
implementation of restrictions is provided in Table 2.
Most respondents (82%) had local guidelines for the 
treatment of infectious diseases available in their hos-
pitals. In 87% of hospitals with local guidelines, recom-
mendations were based on local susceptibility patterns. 
Further information on the availability of guidelines/
standards is provided in Table  2. Only 19% reported to 
have no specific guidance documents in the ICU. 52% of 
participants had a written ICU policy requiring prescrib-
ers to document the indication of antimicrobials in the 
patient records.
The quantity of antimicrobials prescribed was moni-
tored in 56% of ICUs. In these hospitals, daily defined 
doses (DDDs) were the most used statistical measure 
(41%), followed by days of therapy (DOTs) in 29%. 26% 
of participants were unsure of the details of antimicrobial 
usage surveillance in their hospital.
Regarding cumulative antimicrobial susceptibility 
reports, only 70% of participants had these data avail-
able for their ICUs. 17% were uncertain about their 
local status, while 13% reported a complete lack of such 
information.
43% of respondents had a system of mandatory bedside 
consultation by ID specialists for special types of infec-
tions in the ICU. These consultations were designated 
for endocarditis (64%), invasive fungal infections (61%), 
Staphylococcus aureus bacteremia (55%), prosthetic joint 
infection (48%), and infection of vascular prostheses 
(42%).
Part 3: use of TDM and prolonged/continuous infusion 
of antimicrobials
75% of participants had written guidelines for antimicro-
bial dosing in their ICU, where 77% used a local guideline 
and 23% had national guidelines. Therapeutic drug moni-
toring of antimicrobial agents was used in 61% of ICUs. 
Where TDM was available, drug measurements were 
performed by the clinical chemistry service in 63% of 
hospitals, by the clinical pharmacy in 16% of cases and by 
the microbiology department in 11%. Advice on the clini-
cal use of drug measurements was provided by various 
specialists, including intensivists (72%), microbiologists 
(30%), ID specialists (29%), clinical pharmacists (28%), 
and clinical chemistry specialists (14%). Antimicrobials 
available for TDM are listed in Table 2.
To elucidate whether ASP had an association with the 
use of TDM, we compared respondents by their ASP 
Table 2 Details on antimicrobial stewardship programs (ASP) 
and therapeutic drug monitoring (TDM)
Characteristic Numbers (%)
Infection management and ASP
 ASP available in the ICU 499 (63%)
 Any restriction of antimicrobials 478 (62%)
 Availability of local treatment guidelines 619 (82%)
 Quantitative monitoring of antimicrobial use 409 (56%)
 Availability of cumulative antimicrobial susceptibility 
reports
506 (70%)
 Use of therapeutic drug monitoring (TDM) 435 (61%)
 Use of prolonged/continuous infusion of antimicrobials 539 (76%)
Implementation of restriction of antimicrobials
 Antibiotic order forms 198 (41%)
 Pre-authorization 156 (33%)
 Post-authorization 125 (26%)
 Post-prescription review 130 (27%)
 Telephone feedback 114 (24%)
 Formulary restriction 89 (19%)
 Mandatory bedside consultation 91 (19%)
 Computerized alerts 56 (12%)
 Automatic stop orders 43 (9%)
Availability of guidelines/standards
 De-escalation of therapy 410 (50%)
 Duration of therapy 377 (46%)
 Dose optimization 357 (44%)
 Discontinuation 266 (33%)
Antimicrobials with available TDM
 Glycopeptides 387 (89%)
 Aminoglycosides 333 (77%)
 Carbapenems 138 (32%)
 Penicillins 131 (30%)
 Azole antifungals 117 (27%)
 Cephalosporins 76 (17%)
 Linezolid 68 (16%)
 Echinocandin antifungals 66 (15%)
 Colistin 52 (12%)
 Quinolones 44 (10%)
 Daptomycin 36 (8%)
Antimicrobials with prolonged/continuous infusion
 Penicillins 410 (76%)
 Carbapenems 405 (75%)
 Glycopeptides 269 (50%)
 Cephalosporins 163 (30%)
 Linezolid 71 (13%)
 Azole antifungals 39 (7%)
Page 5 of 8Lanckohr et al. Ann. Intensive Care          (2021) 11:131  
status (yes or no, 545 vs. 215, respectively) and their 
reported use of TDM. In the cohort of respondents with 
an ASP, 331 used TDM, while 156 did not (58 respond-
ents did not provide answers to both questions). In com-
parison, in the cohort without availability of an ASP, 95 
respondents used TDM, while 91 did not (29 respond-
ents did not provide answers to both questions). In a uni-
variate analysis, the presence of an ASP had a significant 
association with the use of TDM (odds ratio 2.03 [1.44–
2.87], p < 0.001).
76% of respondents used prolonged and/or continu-
ous infusion of antimicrobials in their ICU (see Table 2 
for list of antimicrobials). 29% of participants had a TDM 
available for every antimicrobial that they give extend-
edly. We did not find an association of the availability of 
an ASP with the use of prolonged or extended infusion of 
antimicrobials. When focusing on beta-lactams specifi-
cally, there was also no significant association.
Part 4: education
In 53% of ICUs, education on antimicrobial stewardship 
was provided to physicians. This training was mandatory 
in 23% of cases, all other ICUs offered education on AMS 
on a voluntary basis. Common topics discussed included 
antimicrobial resistance (88%), streamlining and de-esca-
lation (73%) management of specific syndromes (e.g., S. 
aureus bacteremia, pneumonia, endocarditis) (64%), use 
of TDM (51%), use of restricted agents (50%), oral switch 
(40%), and results from local audits and prevalence sur-
veys (23%).
Discussion
This international survey among intensive care special-
ists adds knowledge to results of previous inquiries that 
have explored the local organization of AMS in the inten-
sive care setting in Germany [17] and France [18]. To the 
best of our knowledge, therapeutic drug monitoring in 
the ICU has only been surveyed once in the past [14] and 
we are able to provide a current perspective on the evolv-
ing use of this technology. The number of participants 
in A-TEAMICU was considerably larger than in those 
surveys.
Slightly more than 60% of respondents have an ID 
specialist and a clinical microbiologist available at their 
hospitals, while the remainder must rely on external con-
sultations or cannot access this resource at all. This find-
ing reflects both the known shortages of ID physicians 
and clinical microbiologists and a growing centralization 
of microbiology services in laboratories detached from 
hospitals [19]. While it is evident that the core respon-
sibility for the management of infections is in the hands 
of the intensivist, the option to acquire specialized input 
should be available, as it is a valuable addition to good 
patient care [20, 21].
Notwithstanding these infrastructural challenges, the 
widespread implementation of formal AMS programs in 
hospitals and ICUs is an encouraging finding, reflecting a 
growing dedication of the medical community to the pre-
vention of AMR. This is all the more encouraging because 
of the documented lack of standardization of training in 
AMS, infectious diseases, and infection prevention in 
many countries [22]. As recommended by contemporary 
guidelines [4], clinical microbiologists, infectious disease 
specialists, and clinical pharmacists are common mem-
bers of the AMS team in hospitals with AMS programs. 
Our results are comparable with the findings of a recent 
survey in four European countries, analyzed AMS on a 
hospital level, albeit without special focus on the ICU 
[15]. In the A-TEAMICU cohort, 77% of respondents 
with an AMS program in their ICU report that the inten-
sivist is a member of the AMS team, demonstrating that 
intensive care medicine specialists are actively engag-
ing in AMS activities. Furthermore, about half of par-
ticipants have received specific training in antimicrobial 
therapy or infection management, adding to the profile of 
the intensivist as “infection manager.”
The availability of local guidelines in 82% of ICUs is a 
finding that warrants attention. The adaption of empiric 
antimicrobial therapy to local epidemiology is essential to 
guarantee adequacy of therapy and simultaneously curb 
overtreatment. Thus, every hospital ought to provide 
such recommendations to their staff. In our survey, 87% 
of hospitals where such guidelines are available incor-
porate local resistance data. Again, this leaves room for 
improvement. On a positive side, a considerable num-
ber of ICUs in the A-TEAMICU cohort have special 
guidelines and recommendation on antimicrobial de-
escalation, duration of therapy, TDM, and antimicrobial 
discontinuation. This finding is encouraging, as it reflects 
recent developments in the field of intensive care medi-
cine [23, 24]. Regarding surveillance in general, cumu-
lative antimicrobial susceptibility reports for the ICU 
are only available in 70% of ICUs and only 56% of par-
ticipants have a monitoring of antimicrobial use. These 
data are indispensable for both therapeutic decisions and 
AMS programs in general and intensivists should actively 
demand the provision of surveillance information.
Therapeutic drug monitoring of anti-infective sub-
stances is widely available in ICUs and intensivists are 
the predominant discipline to advise on the use of TDM 
in the A-TEAMICU cohort. We found an association of 
the use of TDM with the availability of an ASP, which is 
a plausible finding as the pharmacologic optimization 
of antimicrobial is a central tenet of antimicrobial stew-
ardship. In addition to glycopeptide and aminoglycoside 
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antibiotics, approximately 30% of respondents have the 
ability to monitor β-lactams. This proportion is higher 
than expected and demonstrates the growing use of 
pharmacokinetic optimization of antimicrobial therapy 
in the ICU. A recent position paper by ESICM (pub-
lished after A-TEAMICU) explicitly recommends the use 
of β-lactam TDM in critically ill patients [25] and many 
ICUs appear to already pursue these goals.
Concurrent with the finding of an increased use of 
TDM is the extensive use of prolonged and/or continu-
ous infusion of antimicrobials by 76% of respondents. 
As pharmacologically reasonable, this practice predomi-
nantly focuses on β-lactam antibiotics, but 50% also use 
extended infusion regimens for glycopeptides. The latter 
result was unexpected, as current guidelines recommend 
this practice explicitly for patients in whom therapeutic 
targets of vancomycin are not attained with intermittent 
bolus dosing [26]. Whether the continuous infusion of 
vancomycin may also be used to reduce toxicity is still 
a matter of debate. The widespread use of prolonged/
continuous infusion of β-lactams is a surprising devel-
opment from results of previous surveys, where only 
20–30% of participants used this technique [14, 27, 28]. 
Although our questions did not differentiate between 
extended and continuous infusion, we found a clear move 
away from bolus application of time-dependent antibi-
otics. This likely reflects the growing evidence base for 
this therapeutic concept [23]. At the same time, recent 
evidence has identified a need for education on various 
pharmacologic topics related to the use of antimicrobials 
[29]. Of note, in our population we did not find a clear 
association of the use of prolonged/continuous infusions 
with the presence of an ASP. On a practical level, the 
extended infusion of suitable antimicrobials is easier to 
implement than TDM, as the latter has technical require-
ments beyond the ICU. We speculate that intensivist do 
not “need” an ASP to introduce prolonged/continuous 
infusion, whereas the provision of TDM is a more general 
infrastructural challenge for a hospital. Thus, it might be 
argued that an ASP not only propagates the use of TDM 
but also works to provide the possibility to monitor anti-
microbial concentrations. This might be an explanation 
for the influence of an ASP on the use of TDM, without 
a clear influence on the use of prolonged/continuous 
infusion.
Taken together, the results of the A-TEAMICU survey 
provide insight into many aspects of contemporary infec-
tion management in the ICU. As the prevalence of infec-
tions in critically ill patients remains high [7], knowledge 
of diagnostics, antimicrobial pharmacology, and infection 
prevention are essential for the practice of intensive care 
medicine. Antimicrobial stewardship as a “bundle” of 
coordinated actions to optimize the use of antimicrobials 
[30] has established itself in many ICUs and many inten-
sivist are engaged in AMS. Some components of AMS 
have their primary application in the ICU setting, e.g., 
the optimization of antibiotic therapy by means of TDM 
or de-escalation. Thus, intensivists are principle propo-
nents who assume leadership in these topics [10, 12, 31]. 
Professional organizations, like ESICM, might use results 
from A-TEAMICU to expand and refine their engage-
ment on AMS and TDM in intensive care medicine. 
Besides research undertakings, the provision of education 
on infection management appears to be another relevant 
field of activity. This might also include the formulation 
of “best-practice-statements.” A specific example might 
be the availability guidelines for empirical therapy that 
must not only be available but also based on local epide-
miology. ICUs without such guidelines could use recom-
mendations by specialist organizations to advance this 
issue with their hospital management. As the manage-
ment of infections in the ICU needs an interdisciplinary 
framework to achieve the best possible outcomes, spe-
cialist organizations should also assume a leading role in 
the development of interprofessional cooperation.
A limitation of our survey is a probable selection bias 
of participants. The invitation to the survey was primar-
ily distributed to ESICM members, and intensivists not 
affiliated with this society were harder to reach. We tried 
to reduce this bias by asking several national societies 
to use their respective members’ addresses to achieve a 
higher dissemination among the target population. Still, 
it is unlikely that participants outside of these profes-
sional societies took part. Furthermore, respondents with 
a personal interest in infections and antimicrobials are 
more likely to accept an invitation to provide information 
about their current practice. The same probably holds 
true for intensivists who work in an environment (both 
ICU and the hospital as a whole) that has an emphasis 
on infection management and AMS. Therefore, a “posi-
tive” selection of hospitals with a good structure and 
intensivists with a personal dedication to the manage-
ment of infections cannot be excluded. Additionally, we 
cannot exclude the possibility that several participants 
from the same hospital or ICU provided answers. This 
selection bias might also be applicable to the high rate of 
TDM-use. Still, we do not consider this possibility dis-
advantageous, as this might reflect a type of contempo-
rary “best practice.” Lastly, a majority of participants of 
A-TEAMICU came from high-income and upper mid-
dle-income countries, where hospital infrastructure and 
health system funding can be expected to be better than 
in lower-income countries. This will have an influence on 
the availability of staff (e.g., pharmacists, ID specialists) 
and technology (e.g., TDM, laboratory resources), limit-
ing the global generalizability of the survey results.
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A way to reduce potential selection/participation biases 
in future surveys might be a more stringent control of 
participants. As an example, allowing only one person per 
hospital or ICU to provide answers to the survey might 
diminish the impact of institutions where various aspects 
infection management are considered essential and are 
thus endued with sufficient resources. However, this 
might potentially reduce anonymity and thus either pre-
vent colleagues from participation, or introduce a social 
desirability bias, where participants provide answers 
that they consider to be seen as favorable. Besides limi-
tations relevant to participants, the set of questions used 
in A-TEAMICU was not comprehensive with regard to 
the detailed execution of AMS in participating hospitals. 
As an example, we did not assess how feedback on AMS 
interventions was provided to prescribers. This aspect 
and other omissions were necessary to limit the size of 
the questionnaire and the time needed to complete the 
survey. Still, A-TEAMICU focuses on AMS form a pri-
marily intensive care medicine point-of-view and if a par-
ticipant feels that AMS is implemented in their ICU, we 
believe that this is a relevant information. The goal of this 
survey was not to assess a type of “best practice of AMS” 
in ICUs but rather gain insight into the dissemination of 
basic components of ASPs.
In conclusion, many ICU physicians who participated 
in the A-TEAMICU survey have AMS in their ICUs. A 
number of “core elements” of AMS are implemented in 
the respondents’ hospitals (Table 2). Of particular inter-
est, TDM of antimicrobials and optimized administration 
of antibiotics are broadly used.
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